Navigation Links
New way to produce high-vitamin corn could improve nutrition in developing countries
Date:1/17/2008

Scientists have developed a potentially powerful new tool in the fight against deficiencies in dietary vitamin A, which cause eye diseases, including blindness, in 40 million children annually, and increased health risks for about 250 million people, mostly in developing countries.

This tool consists of "a new method of analyzing the genetic makeup of corn that will enable developing countries to identify and increase cultivation of corn that has naturally high levels of vitamin A precursors," says Ed Buckler, a co-leader of the research team from the U.S. Department of Agriculture, Agricultural Research Service and Cornell University

Corn is an essential part of the diets of hundreds of millions of people around the world, many of whom live in developing countries. Regular consumption by adults and children of adequate quantities of corn high in vitamin A precursors, which are converted in the human body into vitamin A, would reduce their chances of developing vitamin A deficiencies and associated health problems.

This new method of increasing cultivation of high-vitamin corn is designed to tap the natural genetic diversity of corn. It was developed by a team led by Buckler and Torbert Rocheford of the University of Illinois, and was partially funded by The National Science Foundation (NSF). It will be described in the January 18, 2007 edition of Science.

"In a field of thousands of ears of corn, each ear has a slightly different genetic makeup and resulting differences in physical characteristics, including levels of vitamin A precursors -- just like every person in a crowd has a slightly different genetic makeup and associated physiological differences," explains James Collins, assistant director for the Biological Sciences Directorate at NSF. But only a very small percentage of corn crops are genetically programmed to have naturally high levels of vitamin A precursors, and these high-vitamin ears cannot be identified me
'/>"/>

Contact: Ed Buckler
esb33@cornell.edu
607-255-4620
National Science Foundation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Biocapture surfaces produced for study of brain chemistry
2. Fresh-cut produce washing practices can minimize food-borne illness risks
3. Chemical compound present in detergents produce bacteria alterations in agricultural soils
4. Researchers examine worlds potential to produce biodiesel
5. Alternative food networks connect ethical producers and consumers and can lead to healthier eating
6. Coal and black liquor can produce energy from papermaking
7. Lipoic acid could reduce atherosclerosis, weight gain
8. Selective restraints and reduced medication could reduce nursing home falls says 4-year study
9. New discovery could reduce the health risk of high-fat foods
10. Deep-sea species loss could lead to oceans collapse, study suggests
11. New technique could dramatically lower costs of DNA sequencing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... from around the world will gather in Boston Nov. ...ets and Cancer Therapeutics International Conferen...on important cancer therapies in development. , ...ctively we need a greater understanding of the act...id Lewis Cantley, Ph.D., director of the cancer ce...
(Date:11/8/2009)...ne through deletion of genetic material on chromos...s in learning and behavior, said a consortium of r....bcm.edu ) in a report that appears online today i...h goes about 95 percent of the way to pinning thes...his gene," said Dr. Arthur L. Beaudet ( http://www...
(Date:11/6/2009)... of the publication of On the Origin of Species, t...) is publishing open access two peer-reviewed arti...s into evolution. , The two articles are by Kevin... and James T. Costa of Western Carolina University...n," appeared in the October issue of the AIBS jour...
Breaking Biology News(10 mins):Developmental delay could stem from nicotinic receptor deletion 2Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4938 1Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4938 2Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4938 3Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4938 4Martek Announces Third Quarter 2009 Financial Results 56082 1Martek Announces Third Quarter 2009 Financial Results 56082 2Martek Announces Third Quarter 2009 Financial Results 56082 3Martek Announces Third Quarter 2009 Financial Results 56082 4Martek Announces Third Quarter 2009 Financial Results 56082 5Martek Announces Third Quarter 2009 Financial Results 56082 6Martek Announces Third Quarter 2009 Financial Results 56082 7Martek Announces Third Quarter 2009 Financial Results 56082 8Martek Announces Third Quarter 2009 Financial Results 56082 9Martek Announces Third Quarter 2009 Financial Results 56082 10Martek Announces Third Quarter 2009 Financial Results 56082 11Martek Announces Third Quarter 2009 Financial Results 56082 12Gentiva 28R 29 Health Services Completes Acquisition of Home Health Agency 56080 1Gentiva 28R 29 Health Services Completes Acquisition of Home Health Agency 56080 2Gentiva 28R 29 Health Services Completes Acquisition of Home Health Agency 56080 3
...he length of nectar spurs--the long tubes leading ...owers to match the tongue lengths of the pollinato... , The researchers were Justen Whittall of the Uni... the University of California at Santa Barbara. Th...(NSF). Their results appear in this week,s issue o...
...ergy and Infectious Diseases (NIAID), a component ...red a survival mechanism in a common type of bacte... bacteria protect itself by warding off attacks fr...e molecules sent by the body to kill bacteria. , B...and gram-negative, with the primary difference bei...
...tations, but just how these mutations contribute t...ew clue comes from scientists at the University of... and Public Health. Their research indicates that ...d, may specifically increase the risk of melanomas...n the NRAS gene, was found in patients who had sun...
Other Biology News:Columbine flowers develop long nectar spurs in response to pollinators 2Newly found sensing system enables certain bacteria to resist human immune defenses 2Sun exposure early in life linked to specific skin cancer gene mutation 2
(Date:11/6/2009)...Austria, November 6 EUCODIS Biosci...ring, and marketing enzymes for the,chemical indus...earch,agreement with Bio Sidus, the leading biopha...he agreement gives EUCODIS Bioscience exclusive ac...Bio Sidus, proprietary collection of,psychrophilic...
(Date:11/6/2009)...if., Nov. 6 Intarcia Therapeutics,...A 650 (DUROS® continuous delivery of exenatid... the Ninth Annual Diabetes Technology Meeting in S....com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,, C...TCA 650 Lowers Plasma Glucose, HbA1c and Reduces W...
(Date:11/5/2009)...Colo., Nov. 5 The endangered black...estern U.S. This rare carnivore feeds on prairie ...lague and often entire population die-offs in town...S) has implemented a ferret breeding program and h...eir formerly native habitat. Unfortunately, plagu...
(Date:11/5/2009)...all on Thursday, November 5, 2009 at 4:30 p.m. Eas.../PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals...XI ) today reported unaudited financial results fo...r 30, 2009 and reviewed the Company,s highlights f...consolidated results reflect the operations of Onc...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
... two-thirds (67%) of Americans are generally conce...pply, according to a 2008 National Consumer Water ...adlines warning of contaminants1 (i.e. lead, radiu... stirred controversy and confusion. Consumers are ...le plastic bottles isn’t an environmentally-...
...ex, Inc. ("ChromaDex"),today announced that effect...I Acquisition, Inc. ("CDI"), the wholly-owned subs...tin Board: CDYE). The transaction,enables ChromaDe... publicly,traded, which will help it be better pos...wing marketplace. The business and operations of C...
...ction Agency Contract Will Support Development o...ial Broad-Spectrum Anti-Viral Ag...euticals, Inc. (Nasdaq: PPHM ), a clinical stage ...tibodies for the treatment of cancer and,hepatitis...ntered into a,five-year contract worth up to $44.4...
Other Biology Technology: Culligan's New Aqua-Cleer Advanced Drinking Water SystemProvides Clean, Quality Water Customized for Every Home 2 Culligan's New Aqua-Cleer Advanced Drinking Water SystemProvides Clean, Quality Water Customized for Every Home 3ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc. 2Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 2Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 3Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 4Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 5
Rabbit Anti-Mouse Junctophilin-4, C-Terminus Monoclonal Antibody, Unconjugated, Clone PADZMD.487 from Invitrogen
...PCR Cloning Kits are designed to speed up the PCR ...s, regardless of sequence or type of polymerase us...ding those that are difficult to clone by other PC...for potentially detrimental proteins can be cloned...
Mounting Medium from BioVision
GeneAmp High Fidelity PCR from Applied Biosystems
Biology Products: